The Efficacy and Cost-Effectiveness of Umeclidinium/Vilanterol versus Tiotropium in Symptomatic Patients with Chronic Obstructive Pulmonary Disease

Table 3

Adverse event rates of UMEC/VI and TIO.

	UMEC/VI	TIO	Source/assumption
N	888	875	NCT01777334, NCT01316913, NCT01316900
Back pain	3.43%	3.30%
Cough	2.81%	2.84%
Headache	9.23%	6.05%
Nasopharyngitis	7.46%	7.40%
Upper respiratory tract infection	3.24%	5.17%